Review Article

Oral Panax notoginseng Preparation for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials

Table 1

Characteristics of trials.

Study IDType of CHD and syndromeMembers (I/C) Age Gender (M/F)Interventions groupControl groupProductOutcome evaluation

Du and Chen 2009 [21]UA56/56 62/50C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular heparin 5–7 days, antihypertensive drugs and medicine used to treat 2 diabetes)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, Z19990022, containing PNS 60 mg/capsule)Angina pectoris (extension, frequency, duration), dosage of nitroglycerin, Ads.

Ge and Zhao 2010 [22]UA48/48I: 56; C: 54 (in average)I: 22/26 V: 25/23C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular heparin 5–7 days, antihypertensive drugs and medicine used to treat 2 diabetes)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming China, Z19990022, containing PNS 60 mg/capsule)Angina pectoris relievement, ECG, Ads.

Han and Chen 2008 [23]PCI patients30/30I: ( ); C: ( )I: 23/7; C: 21/9C + Xuesaitong softy capsule, 2 capsules, BID in the first 2 weeks, then 1 capsule, TID, 12 weeksConventional therapy (anticoagulant agent, antiplatelet agent, medicine for modifying blood lipid, antihypertensive drug and medicine used to treat 2 diabetes)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, Z19990022, containing PNS 60 mg/capsule)Angina pectoris, rehospitalization

Ji and Zhang 2003 [24]UA30/90I1: ( ); I2: ( ); I3: ( ); C: ( )I1: 20/10; I2: 18/12; I3: 21/9; C: 17/13I1: C + coarse power 1 g, TID;
I2: C + semi-micron power 1 g, TID
I3: C + micron power 1 g, TID
Isosorbide Mononitrate 20 mg BID; Aspirin 75 mg, QD; Metoprolol 25 mg BID; DTZ 30 mg, TID or QID; Plendil 5 mg QD or BID or Acertil 4 mg, QD for hypertension; Nitroglycerol 0.5 mg subligual administration or nitroglycerol injection 10 mg, iv.Panax notoginseng coarse power: WF-2000 pulverizer; Panax notoginseng micron power: BFM-6 pulverizer; Panax notoginseng semi-micron power: BFM-6 pulverizer and starch. Efficacy of Angina pectoris, ECG, symptoms, Ads

Liu et al. 2008 [19]UA and BSS30/30I: ( );
C: ( )
UnclearC + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (no detail)Xuesaitong softy capsule (Yunnan weihe Pharmaceutical company, containing PNS 60 mg/capsule)Syndrome, pulse, heart rate, heart rhythm, blood pressure, angina pectoris, ECG

Meng 2003 [25]UA and SA 60/20I: (61–78);
C: (61–78)
I: 44/16 C: 16/4PNS pill, 2 tablets, sublingual when angina pectoris attackedIsosorbide dinitrate when angina pectoris attacked (5 mg/tables)PNS pill, 2 tablet**, SublingualDuration of angina pectoris relievement, blood pressure, heart rate, and ECG after 2 hours of prescription.

Song et al. 2005 [26]Unclear 50/50I: (36–77), ( ); C: (38–74), ( ) in averageI: 31/19 C: 33/17C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular heparin 5–7 days, antihypertensive drugs and medicine used to treat diabetes)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China)Efficacy of angina pectoris, ECG, dosage of nitroglycerin

Wan 2011 [27]UA26/26I: 65.7 in average; C: No reportI: 15/11 C: 13/13C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent and et al.)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China)Efficacy of angina pectoris, ECG

Wang et al. 2009 [28]UA100/10036–75 UnclearT1:C1 + Xuesaitong softy capsule, 2 capsules, BID, 30 days;
T2:C2 + trimetazidine + Xuesaitong softy capsule, 2 capsules, BID, 30 days;
C1: conventional therapy (ant platelet, Nitrates, CCB, β blocker agent, statin, trimetazidine); C2: Conventional therapy (ant platelet, Nitrates, CCB, β blocker agent, astatine)Xuesaitong softy capsuleEfficacy of angina pectoris and cardiovascular events in 30 d followup.

Wei 2010 [29]Unclear90/90 113/67C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (Nitrate, β blocker agent, CCB, low molecular heparin)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China)Angina pectoris, Ads, ECG

Yan 2005 [30]Unclear24/24I: (48–67), 60 in average; C: (47–69), 62 in averageI: 13/11 C: 14/10Isosorbide mononitrat 5 mg TID + Panax notoginseng power 6 g BID, 7 daysIsosorbide Mononitrate, 10 mg, TIDPanax notoginseng power 6 g BIDEfficacy of angina pectoris, ECG, ADs

Yu 2010 [31]UA50/50I: ( ); C: ( )I: 29/21 C: 28/22C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB and et al.)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China)Efficacy of angina pectoris, ECG, ADs, cardiovascular events

Zhou and Bai 2009 [32]Unclear43/43 I: 32/11 C: 34/9C + Xuesaitong softy capsule, 2 capsules, TID, 4 weeksConventional therapy (nitrate, Metoprolol, aspirin, Nitroglycerin if necessary)Xuesaitong softy capsuleΔ (Luotai, Kunming Pharmaceutical incorporated corporation)Efficacy of angina pectoris, ECG

Kuang et al. 2011 [33]UA90/90I: ( );
C: ( )
I: 47/43
C: 46/44
C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular dextran, and others)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, containing PNS 60 mg/capsule)Efficacy of angina pectoris, ECG, ADs

Bao 2011 [34]SA, BSS63/64I: (52.3 in average); C: (51.6 in average)I: 35/28 C: 37/27C + Sanqi guanxinning tablets (Z53020028), 2–4 tables, TID, 6 weeksConventional therapy (nitroglycerin, β blocker agent, and others)Sanqi guanxinning tabletsΔΔ (Z53020028)Efficacy of angina pectoris

Zhao and Li 2012 [35]SA60/58I: ( , 42–70);
C: ( , 41–68)
I: 38/22
C: 40/18
C + Xuesaitong softy capsule, 2 capsules, TID, 4 weeksConventional therapy (aspirin, J20080078, 100 mg) Qd, isosorbide mononitrate (H20030418, 60 mg Qd), β blocker (H32025391)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, Z19990022)Efficacy of ECG

Yang 2012 [36]Unclear14/14( ), 51–7819/9C + Xuesaitong softy capsule, 2 capsules BID in the first two weeks, 1 capsule BID in the later weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, and others)Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, containing PNS 60 mg/capsule)Frequency of angina pectoris, dosage of nitroglycerin, frequency of premature ventricular contraction

BSS: blood stasis syndrome; PNS: panax notoginseng saponins; I: intervention group; C: control group; DTZ: dilthiazem; ECG: electrocardiogram; Ads: adverse event.
*Xuesaitong softy capsule produced by Shenghuo Pharmaceutical Holdings, Yunnan kunming, China (Z19990022) contains PNS 60 mg/capsule.
**There was no purity of PNS pill in this trial. According to the internet, PNS pill produced by Yunnan Weihe Pharmaceutical company contains PNS 50 mg/pill.
ΔXuesaitong softy capsuleΔ (Luotai, Kunming Pharmaceutical incorporated corporation, China) contains PNS 100 mg/capsule.
ΔΔSanqi guanxinning tablets (Z53020028), there is no introduction in the paper about the composition and the purity. According to the internet, Sanqi guanxinning producted by Yunnan JinBuHuan (group) Co., ltd. pharmaceutical branch, containing 100 mg PNS/tablet.